• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks Stalls As Chip Sector Struggles To Rebound; Dollar Eyes 7-Week Peak, Gold, Bitcoin Retreat: What's Driving Markets Friday?

    6/21/24 1:34:54 PM ET
    $FDS
    $HTZ
    $IBB
    $KMX
    Computer Software: Programming, Data Processing
    Technology
    Rental/Leasing Companies
    Consumer Discretionary
    Get the next $FDS alert in real time by email

    Wall Street is experiencing a subdued and low volatility trading day Friday, despite the session coinciding with the “triple witching” day, with over $5.1 trillion of notional options exposure expiring, surpassing the previous record set in December 2023.

    Chipmakers continue to struggle in the aftermath of Thursday’s sell-off, suggesting that while the wave of profit-taking is easing, there is little sign of new buyers stepping in at these levels.

    Nvidia Corp. is down 1.6%, poised to break an eight-week winning streak. The sector benchmark, the iShares Semiconductor ETF (NYSE:SOXX), is witnessing its worst two-day performance since May 1.

    The major indices and sectors remained flat, while biotech stocks showed the strongest performance among industries, with the iShares Biotechnology ETF (NASDAQ:IBB) up 1.9%. Treasury yields were stable, with the 10-year at 4.26%.

    On the macro front, S&P Global reported the strongest growth in U.S. private sector activity in two years, surpassing analyst expectations.

    Gold saw a decline of 1.4%, reversing Thursday’s positive performance. Bitcoin (CRYPTO: BTC) fell 1.8%, heading for its fifth consecutive session of losses, marking the longest losing streak since October 2023.

    Oil prices retreated below $81 per barrel, ending a streak of three consecutive sessions of gains.

    Friday’s Performance In Major US Indices

    Major IndicesPrice1-day %chg
    Russell 20002,019.940.0%
    Dow Jones39,140.670.0%
    S&P 5005,464.09-0.2%
    Nasdaq 10019,694.57-0.3%
    Updated at 12:55 p.m. ET

    According to Benzinga Pro data:

    • The SPDR S&P 500 ETF Trust (NYSE:SPY) was 0.4% lower to $544.76.
    • The SPDR Dow Jones Industrial Average (NYSE:DIA) was 0.2% lower to $391.50.
    • The tech-heavy Invesco QQQ Trust (ARCA: QQQ) was 0.1% lower to $480.81.
    • Sector-wise, the Communication Services Select Sector SPDR Fund (NYSE:XLC) outperformed, up by 0.4%, while the Financials Select Sector SPDR Fund (NYSE:XLF) lagged, falling 0.5%.

    Friday’s Stock Movers

    • Serepta Therapeutics Inc. (NASDAQ:SRPT) rocketed by over 30% after the company announced expanded U.S. FDA approval of ELEVIDYS for Duchenne Muscular Dystrophy patients ages 4 and above.
    • Hertz Global Holdings Inc. (NASDAQ:HTZ) rose over 14%, mimicking Thursday’s move, after the car rental company upsized its bond offering to $1 billion to finance a fleet refresh.
    • FactSet Research Systems Inc. (NYSE:FDS) rose 4% following stronger-than-expected quarterly earnings. CarMax Inc. (NYSE:KMX) was 1% higher in reactions to quarterly results.

    Read now: World’s Biggest S&P 500 ETF Bleeds Outflows: Why Isn’t The Market Crashing? (CORRECTED)

    Photo created using artificial intelligence via MidJourney.

    Get the next $FDS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FDS
    $HTZ
    $IBB
    $KMX

    CompanyDatePrice TargetRatingAnalyst
    FactSet Research Systems Inc.
    $FDS
    2/17/2026$195.00Underperform
    BofA Securities
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    FactSet Research Systems Inc.
    $FDS
    12/17/2025$307.00Underweight → Equal-Weight
    Morgan Stanley
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    CarMax Inc
    $KMX
    11/12/2025$28.00Underweight
    Barclays
    CarMax Inc
    $KMX
    11/10/2025$35.00Overweight → Equal-Weight
    Morgan Stanley
    CarMax Inc
    $KMX
    11/7/2025Outperform → Sector Perform
    RBC Capital Mkts
    CarMax Inc
    $KMX
    11/7/2025Buy → Hold
    Needham
    More analyst ratings

    $FDS
    $HTZ
    $IBB
    $KMX
    SEC Filings

    View All

    SEC Form DEFA14A filed by CarMax Inc

    DEFA14A - CARMAX INC (0001170010) (Filer)

    3/11/26 4:57:05 PM ET
    $KMX
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    FactSet Research Systems Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - FACTSET RESEARCH SYSTEMS INC (0001013237) (Filer)

    3/4/26 6:57:35 AM ET
    $FDS
    Computer Software: Programming, Data Processing
    Technology

    CarMax Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - CARMAX INC (0001170010) (Filer)

    3/2/26 4:56:55 PM ET
    $KMX
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $FDS
    $HTZ
    $IBB
    $KMX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FDS
    $HTZ
    $IBB
    $KMX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

    - Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study - The enhanced immunosuppressive regimen is designed to mitigate the risk of acute liver injury (ALI) and acute liver failure (ALF) associated with AAV gene therapy in non-ambulatory patients Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced screening and enrollment are underway in Cohort 8 of ENDEAVOR (Study 9001-103). The purpose of Cohort 8 is to assess prophylactic sirolimus treatment as part of an enhanced safety protocol during treatment with ELEVIDYS (delandistrogene moxeparvovec-rokl) in

    3/16/26 8:33:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CarMax Issues Statement on Engagement With Starboard Value

    CarMax, Inc. (NYSE:KMX) ("CarMax" or the "Company"), today confirmed that its Board of Directors (the "Board") received a notice from Starboard Value LP ("Starboard"), nominating two directors for election to the Company's Board at the 2026 Annual Meeting of Shareholders and issued the following statement. "CarMax has been taking the necessary steps to ensure that this business delivers on its potential and is responsive to shareholders," said Tom Folliard, Executive Chair of the Board. "Our engagement with Starboard to date has been productive and we remain focused on continued constructive conversations. We are pleased that Starboard agrees with our Board that Keith is the right leader

    3/11/26 10:35:00 AM ET
    $KMX
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    K1 Invests in Spin.AI, a Leader in AI-Powered Cloud Security and Data Protection

    Trusted by 1,500+ organizations worldwide, Spin.AI delivers AI-driven threat detection and automated response across Google Workspace, Microsoft 365, Salesforce, and Slack MANHATTAN BEACH, Calif., March 11, 2026 /PRNewswire/ -- K1 Investment Management, LLC ("K1"), one of the largest investors in small-cap AI-powered software, today officially announced its investment in Spin.AI, a security and data protection platform purpose-built to protect the cloud environments where modern enterprises run some of their most critical operations. Spin.AI addresses a critical gap in enterpris

    3/11/26 10:00:00 AM ET
    $ADP
    $FDS
    $IHRT
    Diversified Commercial Services
    Industrials
    Computer Software: Programming, Data Processing
    Technology

    $FDS
    $HTZ
    $IBB
    $KMX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Revenue Officer Skoko Goran bought $126,465 worth of shares (500 units at $252.93), increasing direct ownership by 6% to 9,192 units (SEC Form 4)

    4 - FACTSET RESEARCH SYSTEMS INC (0001013237) (Issuer)

    11/10/25 4:15:37 PM ET
    $FDS
    Computer Software: Programming, Data Processing
    Technology

    EVP, Chief Financial Officer Shan Helen L. bought $101,928 worth of shares (370 units at $275.48), increasing direct ownership by 4% to 9,284 units (SEC Form 4)

    4 - FACTSET RESEARCH SYSTEMS INC (0001013237) (Issuer)

    10/8/25 4:28:08 PM ET
    $FDS
    Computer Software: Programming, Data Processing
    Technology

    Director Oneil Mark F bought $499,807 worth of shares (10,816 units at $46.21), increasing direct ownership by 78% to 24,690 units (SEC Form 4)

    4 - CARMAX INC (0001170010) (Issuer)

    10/6/25 4:11:10 PM ET
    $KMX
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $FDS
    $HTZ
    $IBB
    $KMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $FDS
    $HTZ
    $IBB
    $KMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    BofA Securities resumed coverage on FactSet with a new price target

    BofA Securities resumed coverage of FactSet with a rating of Underperform and set a new price target of $195.00

    2/17/26 7:37:46 AM ET
    $FDS
    Computer Software: Programming, Data Processing
    Technology

    Barclays resumed coverage on Sarepta Therapeutics with a new price target

    Barclays resumed coverage of Sarepta Therapeutics with a rating of Equal Weight and set a new price target of $20.00

    1/28/26 7:19:11 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FactSet upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded FactSet from Underweight to Equal-Weight and set a new price target of $307.00

    12/17/25 8:43:53 AM ET
    $FDS
    Computer Software: Programming, Data Processing
    Technology

    Chief Operating Officer Estepan Ian Michael covered exercise/tax liability with 1,097 shares, decreasing direct ownership by 0.54% to 201,983 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    3/13/26 8:09:03 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Wong Ryan Ho-Yan covered exercise/tax liability with 256 shares, decreasing direct ownership by 0.19% to 135,064 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    3/13/26 8:07:03 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, R&D and Tech Ops Rodino-Klapac Louise covered exercise/tax liability with 948 shares, decreasing direct ownership by 0.42% to 225,323 units (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    3/13/26 8:05:03 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FDS
    $HTZ
    $IBB
    $KMX
    Leadership Updates

    Live Leadership Updates

    View All

    Starboard Delivers Letter to CarMax

    Views Appointment of New CEO Keith Barr as Timely Opportunity to Address Fixable Execution Gaps and Unlock CarMax's Full Value Potential Has Nominated Directors to Help Support the Next Phase of Execution and Accelerate Shareholder Value Creation Believes CarMax's Structurally Superior Omnichannel Model Is Not Reflected in Current Performance Sees Clear Opportunities to Drive Improvement Through Enhanced Digital Execution, Reconditioning Efficiencies and Dynamic Pricing Urges a Substantially Expanded SG&A Reduction Program to Restore Cost Discipline and Enhance Long-Term Earnings Power Starboard Value LP (together with its affiliates, "Starboard"), a significant stockholder of Car

    3/11/26 8:00:00 AM ET
    $KMX
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    CarMax Names Keith Barr as Chief Executive Officer

    CarMax, Inc. (NYSE:KMX) ("CarMax" or the "Company") today announced that Keith Barr has been appointed President and Chief Executive Officer, and a member of the Board of Directors ("the Board"), effective March 16, 2026. David McCreight, current Interim President and CEO of CarMax, will transition to his prior duties as an independent Director of the Board. Tom Folliard will remain in his role as Interim Executive Chair of the Board until the Company's Annual Meeting in June 2026, after which he is expected to resume his prior duties as non-executive Chair of the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026021283385

    2/12/26 6:50:00 AM ET
    $IHG
    $KMX
    Hotels/Resorts
    Consumer Discretionary
    Retail-Auto Dealers and Gas Stations

    Barclays and FactSet enter a multiyear strategic agreement

    NORWALK, Conn., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Barclays today announced a multiyear arrangement with FactSet (NYSE:FDS, NASDAQ:FDS), a global financial digital platform and enterprise solutions provider, as a further step in realizing Barclays' long-term market data strategy. This collaboration harnesses FactSet's advanced analytics and innovative technology, empowering Barclays to deliver enhanced, data-driven solutions for its global client base. "Market data is undergoing an intense period of change whereby customers of market data providers are evolving from consumers to co-creators of capabilities to yield competitive insights," said Georges Lauchard, Investment Bank COO at Barcla

    1/22/26 8:45:00 AM ET
    $FDS
    Computer Software: Programming, Data Processing
    Technology

    $FDS
    $HTZ
    $IBB
    $KMX
    Financials

    Live finance-specific insights

    View All

    FactSet Schedules Second Quarter 2026 Earnings Call

    NORWALK, Conn., Feb. 26, 2026 (GLOBE NEWSWIRE) -- FactSet (NYSE:FDS, NASDAQ:FDS), a global financial digital platform and enterprise solutions provider, today announced it will release its financial and operating results for the second quarter fiscal 2026, ending February 28, 2026, on Tuesday, March 31, 2026. FactSet will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results, followed by a live Q&A session. Second Quarter Fiscal 2026 Conference Call Details Date:Tuesday, March 31, 2026  Time:9:00 a.m. Eastern Time  Registration:FactSet Q2 2026 Earnings Call Registration Please register for the conference call using the above link in advance of the call s

    2/26/26 7:00:00 AM ET
    $FDS
    Computer Software: Programming, Data Processing
    Technology

    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

    Net product revenues for the full year 2025 totaled $1,864.3 million, consisting of $965.6 million of PMO net product revenue and $898.7 million of ELEVIDYS net product revenue Net product revenues for the fourth quarter 2025 totaled $369.6 million, consisting of $259.2 million of PMO net product revenue and $110.4 million of ELEVIDYS net product revenue Following refinancing of 2027 notes and corporate restructuring, overall financial position and capital structure strengthened to support full investment in our pipeline and marketed therapies Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for

    2/25/26 4:05:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 25, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2025 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After register

    2/11/26 8:30:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FDS
    $HTZ
    $IBB
    $KMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by FactSet Research Systems Inc.

    SC 13G - FACTSET RESEARCH SYSTEMS INC (0001013237) (Subject)

    10/16/24 12:19:51 PM ET
    $FDS
    Computer Software: Programming, Data Processing
    Technology

    Amendment: SEC Form SC 13D/A filed by Hertz Global Holdings Inc

    SC 13D/A - HERTZ GLOBAL HOLDINGS, INC (0001657853) (Subject)

    7/2/24 8:50:48 PM ET
    $HTZ
    Rental/Leasing Companies
    Consumer Discretionary